New study explores Kidney-Friendly hepatitis b drug for transplant patients
Disease control
Not yet recruiting
This phase 2 trial will enroll 82 stable liver transplant recipients with chronic hepatitis B to see if switching to entecavir orally disintegrating tablets (ETV-ODT) is safe and helps preserve kidney function. Participants will take the drug daily for 48 weeks, and researchers w…
Phase: PHASE2 • Sponsor: Jongman Kim • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC